CNSP News and Press, CNS Pharmaceuticals Inc. From 01/31/24

A look at the top 10 most actives in the United States Remark Holdings Inc. (MARK) rose 264.4% to $1.25 on volume of 238,216,008 shares Advanced Micro Devices Inc. (AMD) fell 3.2% to $172.06 on volume of 122,265,677 shares Phunware Inc. (PHUN) fell 1.0% to $0.2893 on volume of 119,416,884...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced the pricing of its public offering. According to the announcement, the “reasonable best...

2024-01-30 02:19:13 ET More on CNS Pharmaceuticals Financial information for CNS Pharmaceuticals Read the full article on Seeking Alpha For further details see: CNS Pharmaceuticals prices $4M public offering

HOUSTON, TX / ACCESSWIRE / January 29, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the pricing ...

A South Korean research team has discovered a novel brain scan technique that has the potential to revolutionize glioblastoma diagnosis and treatment. Led by Severance Hospital’s Professor Yun Mijin and Director C. Justin Lee from the Center for Cognition and Sociality, the research the ...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has appointed a biotech veteran to its board of directors. The company announced that Amy Mahery, a high...

Highly accomplished biopharmaceutical industry executive with successful track record in the commercialization and launch of drugs in varied therapeutic areas including oncology, neurology, and immunology HOUSTON, TX / ACCESSWIRE / January 18, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)...

HOUSTON, TX / ACCESSWIRE / January 17, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced completi...

2024-01-14 03:40:00 ET Summary Shanghai Argo Biopharma entered two agreements with Novartis for a total value of $4.2 billion. San Diego’s Ambrx Biopharma will be acquired by Johnson & Johnson for $2 billion. GSK plans to acquire Aiolos Bio, a San Francisco-London s...

A new multidisciplinary consortium is combining knowledge from several different disciplines to develop new methods for diagnosing and treating gliomas. Comprised of Sweden’s Umeå University and Umeå University Hospital and PSE Data Security from Switzerland, the consortium wil...